225 related articles for article (PubMed ID: 25381969)
1. Management of patients with psoriasis treated with biological drugs needing a surgical treatment.
Fabiano A; De Simone C; Gisondi P; Piaserico S; Lasagni C; Pellacani G; Conti A
Drug Dev Res; 2014 Nov; 75 Suppl 1():S24-6. PubMed ID: 25381969
[TBL] [Abstract][Full Text] [Related]
2. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.
Hession MT; Gottlieb AB
J Dermatolog Treat; 2011 Apr; 22(2):90-101. PubMed ID: 20673155
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal gammopathy of undetermined significance in patients with psoriasis: is it really a side effect of biological therapy?
Conti A; Esposito I; Lasagni C; Miglietta R; Padalino C; Fabiano A; Pellacani G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S35-7. PubMed ID: 25381972
[TBL] [Abstract][Full Text] [Related]
4. Viewpoint on handling anti-TNF failure in psoriasis.
Bracke S; Lambert J
Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
[TBL] [Abstract][Full Text] [Related]
5. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
[No Abstract] [Full Text] [Related]
6. Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-α inhibitor therapy.
Varley CD; Deodhar AA; Ehst BD; Bakke A; Blauvelt A; Vega R; Yamashita S; Winthrop KL
Rheumatology (Oxford); 2014 Feb; 53(2):332-7. PubMed ID: 24173434
[TBL] [Abstract][Full Text] [Related]
7. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
8. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
Cozzani E; Burlando M; Parodi A
G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
[TBL] [Abstract][Full Text] [Related]
9. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
[TBL] [Abstract][Full Text] [Related]
12. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
Alsharqi A; Parslew R; Dever B; Arslanian V
Australas J Dermatol; 2012 May; 53(2):e45-7. PubMed ID: 22571585
[No Abstract] [Full Text] [Related]
13. Inflammatory/infectious cutaneous side effects of biological drugs in patients with psoriasis: a general review with personal data.
Rongioletti F; Burlando M; Parodi A
G Ital Dermatol Venereol; 2014 Jun; 149(3):311-6. PubMed ID: 24819758
[TBL] [Abstract][Full Text] [Related]
14. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
16. Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatment.
Prignano F; Pescitelli L; Ricceri F; Ermini A; Lotti T
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1444-8. PubMed ID: 21834947
[TBL] [Abstract][Full Text] [Related]
17. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy.
Bardazzi F; Odorici G; Virdi A; Antonucci VA; Tengattini V; Patrizi A; Balestri R
J Dtsch Dermatol Ges; 2014 May; 12(5):401-6. PubMed ID: 24797746
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
20. Effects of TNF-alpha inhibitors on circulating Th17 cells in patients affected by severe psoriasis.
Piaserico S; Sandini E; Saldan A; Abate D
Drug Dev Res; 2014 Nov; 75 Suppl 1():S73-6. PubMed ID: 25381985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]